Biogen Idec ( BIIB) and its partner Elan ( ELN) said data from two late-stage clinical trials of the multiple sclerosis drug Tysabri have been published in the New England Journal of Medicine. Results included those from the phase III trial dubbed Affirm, which examined Tysabri used by itself, and a phase III trial called Sentinel that studied Tysabri used with the Biogen Idec MS drug Avonex. According to the Affirm trial, Tysabri used alone reduced the risk of an MS patient's disability worsening by 42% and showed a 68% reduction in the rate of relapse each year when compared with a placebo. Treatment with Tysabri also resulted in significant and sustained reductions in brain-lesion activity, according to the companies. The Sentinel trial found that Tysabri plus Avonex had a significant effect on hampering the progression of MS, the relapse rate and brain-disease activity vs. Avonex alone. Last year, Tysabri was pulled from the market after it was linked to a potentially fatal brain disease called progressive multifocal leukoencephalopathy. In all, three cases of the condition were found, but safety evaluations uncovered no additional episodes of PML. A Food and Drug Administration advisory committee is scheduled to meet for two days next week to decide whether the drug can again go on sale. Biogen's shares tacked on 5 cents to $47 in after-hours trading Wednesday, and Elan rose 11 cents to $13.10.